Suppression of abnormal karyotype predicts superior survival in multiple myeloma.

Leukemia
V ArzoumanianB Barlogie

Abstract

Cytogenetic studies were performed as part of all diagnostic and surveillance bone marrow examinations in 956 newly diagnosed patients with multiple myeloma (MM) receiving total therapy (TT) protocols and in 1085 previously treated patients enrolled in non-TT protocols. In both groups, cytogenetic abnormalities (CA) were present in one-third at baseline and persisted in 14% prior to first and 10% prior to second transplant (TT, 5%; non-TT, 15%); post-transplant detection rates increased progressively with time, from 7% within 6 months to 21% within 24 months to 28% at relapse. According to multivariate analyses, overall survival was adversely affected by the presence of CA at baseline (hazard ratio (HR)=7.20, P<0.001) and the development of CA both prior to (HR=3.28, P<0.001) and after first transplant (HR=6.24, P<0.001), whereas suppression of CA pretransplant was favorable (HR=0.38, P<0.001). The presence of CA at relapse further distinguished patients with a short median post-relapse survival of only 11 versus 47 months in those without CA (P<0.0001). Post-relapse survival was independently adversely affected by the detection of CA both at baseline (HR=1.35, P=0.044) and relapse (HR=2.47, P<0.001). Collectively, these result...Continue Reading

References

Aug 1, 1985·The Journal of Clinical Investigation·B BarlogieL Smith
Jul 1, 1995·Cancer Genetics and Cytogenetics·J R SawyerB Barlogie
Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G TricotB Barlogie
May 12, 1998·British Journal of Haematology·C SeongR Alexanian
Mar 3, 2004·Cancer Research·Rafael FonsecaHerve Avet-Loiseau
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Mar 10, 2006·The New England Journal of Medicine·Bart BarlogieJohn Crowley
May 27, 2006·Blood·Fenghuang ZhanJohn D Shaughnessy
Aug 31, 2006·British Journal of Haematology·Bart BarlogieJohn Crowley
Jun 27, 2007·British Journal of Haematology·Bart BarlogieJohn D Shaughnessy
Dec 7, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey HaesslerBart Barlogie

❮ Previous
Next ❯

Citations

Jul 30, 2009·Blood·Jean-Luc HarousseauHerve Avet-Loiseau
Aug 8, 2008·Leukemia·P G RichardsonK C Anderson
Dec 17, 2008·Hematology·Jean-Luc Harousseau
Nov 5, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yogesh S JethavaFrits van Rhee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.